- Home
- IMVT vs APLS Comparison
IMVT vs APLS Comparison
Compare IMVT & APLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMVT
- APLS
- Stock Information
- Founded
- IMVT N/A
- APLS 2009
- Country
- IMVT United States
- APLS United States
- Employees
- IMVT N/A
- APLS N/A
- Industry
- IMVT Biotechnology: Biological Products (No Diagnostic Substances)
- APLS Biotechnology: Pharmaceutical Preparations
- Sector
- IMVT Health Care
- APLS Health Care
- Exchange
- IMVT Nasdaq
- APLS Nasdaq
- Market Cap
- IMVT 2.5B
- APLS 2.2B
- IPO Year
- IMVT N/A
- APLS 2017
- Fundamental
- Price
- IMVT $14.85
- APLS $16.93
- Analyst Decision
- IMVT Buy
- APLS Buy
- Analyst Count
- IMVT 10
- APLS 19
- Target Price
- IMVT $40.14
- APLS $37.50
- AVG Volume (30 Days)
- IMVT 1.2M
- APLS 2.9M
- Earning Date
- IMVT 05-29-2025
- APLS 05-07-2025
- Dividend Yield
- IMVT N/A
- APLS N/A
- EPS Growth
- IMVT N/A
- APLS N/A
- EPS
- IMVT N/A
- APLS N/A
- Revenue
- IMVT N/A
- APLS $775,839,000.00
- Revenue This Year
- IMVT $108.88
- APLS $1.54
- Revenue Next Year
- IMVT N/A
- APLS $22.80
- P/E Ratio
- IMVT N/A
- APLS N/A
- Revenue Growth
- IMVT N/A
- APLS 48.04
- 52 Week Low
- IMVT $12.72
- APLS $16.10
- 52 Week High
- IMVT $34.47
- APLS $43.76
- Technical
- Relative Strength Index (RSI)
- IMVT 50.48
- APLS 41.44
- Support Level
- IMVT $13.79
- APLS $16.61
- Resistance Level
- IMVT $15.22
- APLS $17.48
- Average True Range (ATR)
- IMVT 0.69
- APLS 0.86
- MACD
- IMVT 0.13
- APLS 0.09
- Stochastic Oscillator
- IMVT 78.24
- APLS 28.47
About IMVT Immunovant Inc.
Immunovant Inc is a clinical-stage biopharmaceutical company. It is focused on enabling normal lives for patients with autoimmune diseases. The company's product includes batoclimab and IMVT-1402 targets the neonatal Fc receptor (FcRn).
About APLS Apellis Pharmaceuticals Inc.
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.